Amgen Leverages T-cells in Cancer Fight with BiTE Technology

Biotechnology firm Amgen is developing cancer immunotherapies by utilizing its Bispecific T-cell Engager (BiTE) technology. This therapeutic approach harnesses the patient's own T-cells to target and destroy cancer cells.

BiTE molecules function as a bridge, connecting a cancer cell to a T-cell. One part of the engineered protein binds to a specific target on the cancer cell's surface, while the other part binds to the CD3 complex on a T-cell. This binding activates the T-cell, prompting it to attack and eliminate the cancerous cell.

The technology builds on the understanding that T-cells are critical components of the immune system, capable of recognizing and eliminating foreign or abnormal cells. BiTE technology effectively equips these T-cells with the ability to identify and engage cancer cells that they might not naturally target.

Amgen reports that this approach aims to enhance treatment specificity, reduce side effects, and improve the overall prognosis and quality of life for cancer patients. The company has explained the principles of BiTE technology and its benefits for patients in interviews, highlighting its potential application across various cancer types based on specific tumor antigens.